Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLB1 | P16278 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13146119 | 1.00 | GLB1 (0.38) | GLB1CA2CA1CA9LMNA | |
| SCHEMBL18685056 | 1.00 | GLB1 (0.38) | GLB1CA2CA1CA9LMNA | |
| SCHEMBL29329357 | 0.79 | CA2 (0.41) | GLB1CA2CA1CA9LMNA | |
| SCHEMBL19132623 | 0.79 | CA2 (0.41) | GLB1CA2CA1CA9LMNA | |
| SCHEMBL16907935 | 0.79 | CA2 (0.41) | GLB1CA2CA1CA9LMNA | |
| SCHEMBL15691484 | 0.79 | CA2 (0.41) | GLB1CA2CA1CA9LMNA | |
| SCHEMBL12408768 | 0.79 | CA2 (0.41) | GLB1CA2CA1CA9LMNA | |
| SCHEMBL8960307 | 0.79 | CA2 (0.41) | GLB1CA2CA1CA9LMNA | |
| SCHEMBL7152794 | 0.77 | CA2 (0.40) | GLB1CA2CA1CA9LMNA | |
| SCHEMBL12248122 | 0.76 | ALDH1A1 (0.31) | CA2CA1CA9ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190099436-A1 | SODIUM GLUCOSE CO-TRANSPORTER INHIBITORS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2019-04-04 | — | — | US | disclosed |
| US-20170087172-A1 | SODIUM GLUCOSE CO-TRANSPORTER INHIBITORS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2017-03-30 | — | — | US | disclosed |
| US-9365602-B2 | Sodium glucose co-transporter inhibitors and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20140135277-A1 | SODIUM GLUCOSE CO-TRANSPORTER INHIBITORS AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2014-05-15 | — | — | US | disclosed |
| EP-2308841-B1 | Phlorizin analogs as SGLT2 inhibitors | LEXICON PHARMACEUTICALS INC (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8476413-B2 | Sulfanyl-tetrahydropyran-based compounds and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476413-B2 | Sulfanyl-tetrahydropyran-based compounds and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| EP-2308841-A2 | Phlorizin analogs as SGLT2 inhibitors | Lexicon Pharmaceuticals, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| EP-2089361-B1 | INHIBITORS OF SODIUM GLUCOSE CO-TRANSPORTER 2 AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20100311673-A1 | SULFANYL-TETRAHYDROPYRAN-BASED COMPOUNDS AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2010-12-09 | — | — | US | disclosed |
| US-20100311673-A1 | SULFANYL-TETRAHYDROPYRAN-BASED COMPOUNDS AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2010-12-09 | — | — | US | disclosed |
| US-7846945-B2 | Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2010-12-07 | — | — | US | disclosed |
| US-7846945-B2 | Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2010-12-07 | — | — | US | disclosed |
| US-7781577-B2 | 2-[4-Chloro-3-(4-hydroxy-benzyl)-phenyl]-6-methoxy-tetrahydro-pyran-3,4,5-triol; 2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-piperidine-1-carboxylic acid methyl ester; (2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-methoxytetrahydro-2H-thiopyran-3,4,5-triol; antidibetic, antiobesity agents | LEXICON PHARMACEUTICALS, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-7781577-B2 | 2-[4-Chloro-3-(4-hydroxy-benzyl)-phenyl]-6-methoxy-tetrahydro-pyran-3,4,5-triol; 2-[4-Chloro-3-(4-ethoxy-benzyl)-phenyl]-3,4,5-trihydroxy-piperidine-1-carboxylic acid methyl ester; (2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-methoxytetrahydro-2H-thiopyran-3,4,5-triol; antidibetic, antiobesity agents | LEXICON PHARMACEUTICALS, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20080221164-A1 | Inhibitors of Sodium Glucose Co-Transporter 2 and Methods of Their Use | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2008-09-11 | — | — | US | disclosed |
| US-20080221164-A1 | Inhibitors of Sodium Glucose Co-Transporter 2 and Methods of Their Use | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2008-09-11 | — | — | US | disclosed |
| US-20080113922-A1 | INHIBITORS OF SODIUM GLUCOSE CO-TRANSPORTER 2 AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2008-05-15 | — | — | US | disclosed |
| US-20080113922-A1 | INHIBITORS OF SODIUM GLUCOSE CO-TRANSPORTER 2 AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113922-A1 | INHIBITORS OF SODIUM GLUCOSE CO-TRANSPORTER 2 AND METHODS OF THEIR USE | SLC2A1, SLC2A2, SLC5A2 | GLB1 527/4885CA2 356/4885CA1 2703/4885 |
| US-20170087172-A1 | SODIUM GLUCOSE CO-TRANSPORTER INHIBITORS AND METHODS OF THEIR USE | SLC2A1, SLC2A4, SLC5A2 | GLB1 373/4885CA2 711/4885CA1 2767/4885 |
| US-20190099436-A1 | SODIUM GLUCOSE CO-TRANSPORTER INHIBITORS AND METHODS OF THEIR USE | SLC2A1, SLC2A4, SLC5A2 | GLB1 373/4885CA2 711/4885CA1 2767/4885 |
| US-20100311673-A1 | SULFANYL-TETRAHYDROPYRAN-BASED COMPOUNDS AND METHODS OF THEIR USE | GPR119, FABP4, LIPC | GLB1 376/4885CA2 4707/4885CA1 4669/4885 |
| US-20140135277-A1 | SODIUM GLUCOSE CO-TRANSPORTER INHIBITORS AND METHODS OF THEIR USE | SLC2A1, SLC2A4, SLC5A2 | GLB1 373/4885CA2 711/4885CA1 2767/4885 |
| US-20080221164-A1 | Inhibitors of Sodium Glucose Co-Transporter 2 and Methods of Their Use | SLC2A1, SLC2A2, SLC5A2 | GLB1 527/4885CA2 356/4885CA1 2703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.